DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for maturity-onset diabetes of the young — screening already-approved drugs against its 13-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMaturity-onset diabetes of the young maps to a 13-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside maturity-onset diabetes of the young in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
insulin (INS) — INS is one of the genes in this disease's Open Targets module — part of the target space DeCure's repurposing candidates point at. The protein backbone is drawn as a cartoon. The structure has 4'-hydroxycinnamic acid bound in it, shown as sticks.
Loading structure…
helix sheet hc4drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6TC2 · 1.36 Å · ligand 4'-HYDROXYCINNAMIC ACID (HC4). Experimental structure, not a prediction.
What the evidence adds up to
All recognised forms of MODY are dominantly inherited, and a 2021 hypothesis proposes that recessive MODY variants do exist but have escaped detection because they lack a family history suggestive of monogenic inheritance. A 2025 report on a new MODY subtype from India (MODY 15) notes that the original classification of diabetes was based purely on age at onset: those diagnosed below 40 years were labelled "growth onset diabetes" and those at or above 40 years "maturity onset diabetes," which were then believed to be equivalent to type 1 and type 2 diabetes respectively. A 2007 review of therapy in children with diabetes discusses debate about whether childhood-onset years count as much as later-onset years for complication development, and states that several studies indicate intensive management at younger ages, while difficult, provides long-term benefit.
No concrete numbers on survival, response rates, or sample sizes are given in any of these abstracts. The 2021 and 2022 abstracts are identical hypothesis papers that do not report clinical data. The 2025 abstract is a discovery report that does not provide quantitative results. The 2007 review mentions "several studies" but gives no specific figures.
The evidence is therefore entirely conceptual or historical. No drug is mentioned in any abstract. No treatment recommendation can be made. The hypothesis that recessive MODY exists remains untested, and the MODY 15 subtype from India has no published clinical outcomes. What is still missing is any clinical trial data, any patient stratification beyond age at diagnosis, and the funding needed to search for recessive MODY families or to characterise the new subtype with measurable endpoints.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1970 · 10 citations
Diabetes and the Amplifier Hypothesis
AbstractThis week's report by Rosenbloom on the occurrence of "chemical" diabetes in children is important because of its optimistic implications. If juvenile diabetes were fundamentally different from the maturity-onset type and characterized from the start by the sudden disappearance of insulin secretory capacity there might be some justification for routine acceptance of the conventional therapeutic approach. Rosenbloom's observations, however, confirm scattered earlier reports to indicate that children in whom clinical disease is destined to develop pass through a phase of nearly asymptomatic but nonetheless, by modern laboratory technics, easily detected preclinical diabetes. At this point treatment with oral antidiabetic agents . . .
Clinical Studies of Tolazamide and Tolbutamide: Comparative Effectiveness of Control of Diabetes Mellitus
AbstractTolazamide, a new oral hypoglycemic agent, was compared with tolbutamide, a related chemical compound, for stability of control of 12 patients suffering from maturity-onset diabetes mellitus. A short 12-week study was conducted which incorporated a cross-over design and the results were examined by variance analysis after dosage was individualized to the patient's requirements. Greater stability of fasting blood sugar was found on tolazamide; patients also had less glycosuria and lower fasting blood sugar on tolazamide. Tolazamide appeared to be between five and six times as potent as tolbutamide, mg. for mg.No hepatic, renal, hematologic or symptomatic toxic reactions were observed during the total of 72 person-weeks of tolazamide therapy.
Trends in Genetics · 2021 · 3 citations · open access
Why all MODY variants are dominantly inherited: a hypothesis
AbstractMaturity-onset diabetes in the young (MODY) comprises monogenic phenotypes of young-onset, insulinopenic diabetes. All its forms are dominantly inherited. Why? Are the pancreatic β cells only harmed by heterozygous variants? We propose that recessive MODYs do exist but have escaped detection due to lack of family history suggestive of monogenic inheritance.
Current Medical Research and Opinion · 1975 · 2 citations
Long-term clinical study of glipizide
AbstractSummaryTwenty-eight patients with maturity onset diabetes were treated with glipizide and studied for periods up to 30 months. Dosage ranged from 5 to 40 mg. daily, most patients requiring 20 mg. daily for satisfactory control: 40% also required biguanide. The poorest response to treatment was in those patients who had failed to respond to other sulohonylureas.Biological tolerance of glipizide was good, except in 2 patients who had raised alkaline phosphatase levels. There were no significant changes in serum cholesterol, plasma triglycerides, or lipoprotein electrophoretic measurements.Key Words:: Glipizideantidiabeticsdiabetes mellitus
Journal of the Association of Physicians of India · 2025 · 1 citations
Exciting Discovery of a New Maturity-onset Diabetes of the Young Subtype from India (MODY 15)
AbstractAt that time, the classification of diabetes was based purely on the age at onset of diabetes. Those diagnosed with diabetes below 40 years of age were labeled as "growth onset diabetes," while those with onset at or above the age of 40 years were referred to as "maturity onset diabetes." At that time, these types were believed to be equivalent to what are known as type 1 diabetes (T1D) and type 2 diabetes (T2D) today.
Why all MODY variants are dominantly inherited: a hypothesis.
AbstractMaturity-onset diabetes in the young (MODY) comprises monogenic phenotypes of young-onset, insulinopenic diabetes. All its forms are dominantly inherited. Why? Are the pancreatic β cells only harmed by heterozygous variants? We propose that recessive MODYs do exist but have escaped detection due to lack of family history suggestive of monogenic inheritance.
AbstractThere has been much debate about the development of complications due to diabetes that has its onset in the childhood years, with some arguing that these years don't count as much as when diabetes develops later on in life. This article discusses the results of several studies indicating that intensive management at younger ages, while difficult, provides long-term benefit.
AbstractDiabetes mellitus is a chronic disease of inconvenience. Proper management of the child with this disorder ensures normal growth and development and delays the onset of the degenerative complications. general medical care of the child with diabetes mellitus should differ in no way from the general medical management of his non-diabetic contemporary. These children should engage in full, unrestricted activity and receive the same health measures as the non-diabetic child. This quotation from the preface of the book summarizes the authors' philosophy about childhood diabetes. To quote again from the preface, The purpose of this book is to provide a concise, practical method of management of juvenile diabetes mellitus. This is done briefly and clearly with short initial chapters on etiology, diagnosis, the insulins, and instruction of the patients and parents about diabetes, which includes an ABC on urine testing and insulin administration. By far the longest chapter is
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
